Understanding the burden of pneumococcal disease in adults

被引:133
作者
Blasi, F. [1 ]
Mantero, M. [1 ]
Santus, PierAchille [2 ]
Tarsia, P. [1 ]
机构
[1] Univ Milan, IRCCS Fdn Osped Maggiore Policlin Ca Granda Milan, Resp Med Sect, Dipartimento Toraco Polmonare & Cardiocircolatori, I-20122 Milan, Italy
[2] Univ Milan, IRCCS Fdn Salvatore Maugeri, Dipartimento Toraco Polmonare & Cardiocircolatori, I-20122 Milan, Italy
关键词
Antibiotic resistance; cost of disease; infection prevention; Streptococcus pneumoniae; vaccine; COMMUNITY-ACQUIRED PNEUMONIA; DOUBLE-BLIND TRIAL; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE-VACCINE; POLYSACCHARIDE VACCINE; UNITED-STATES; ANTIMICROBIAL RESISTANCE; PREVENTING PNEUMONIA; MACROLIDE RESISTANCE; BACTERIAL PNEUMONIA;
D O I
10.1111/j.1469-0691.2012.03937.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clin Microbiol Infect 2012; 18 (Suppl. 5): 714 Abstract Streptococcus pneumoniae causes different types of acute, invasive and non-invasive clinical infections, being the most frequently detected pathogen responsible for community-acquired pneumonia. Pneumococcal pneumonia is accompanied by bacteraemia in 1030% of cases. Streptococcus pneumoniae is gaining resistance to the in vitro activity of several antimicrobial agents and, even if questions remain regarding the clinical impact of this phenomenon, more and more reports indicate that antibiotic resistance can lead to more treatment failures if not higher mortality. Use of the 23-valent anti-pneumococcal vaccine appears to offer subpotimal protection against pneumococcal disease, particularly among high-risk adult populations. Vaccination against S. pneumoniae with new conjugate vaccines seems to be the most promising field for real improvement in the management of pneumococcal infections in adults.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 70 条
[1]   Cost-effectiveness of pneumococcal vaccination of older people:: A study in 5 western European countries [J].
Ament, A ;
Baltussen, R ;
Duru, G ;
Rigaud-Bully, C ;
de Graeve, D ;
Örtqvist, Å ;
Jönsson, B ;
Verhaegen, J ;
Gaillat, J ;
Christie, P ;
Cifre, AS ;
Vivas, D ;
Loiseau, C ;
Fedson, DS .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :444-450
[2]   Community-acquired pneumonia [J].
Andrews, J ;
Nadjm, B ;
Gant, V ;
Shetty, N .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (03) :175-180
[3]  
[Anonymous], 1996, MMWR Recomm Rep, V45, P1
[4]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[5]  
[Anonymous], 2003, European Lung White Book, V2nd, P55
[6]   A population-based study of the costs of care for community-acquired pneumonia [J].
Bartolomé, M ;
Almirall, J ;
Morera, J ;
Pera, G ;
Ortún, V ;
Bassa, J ;
Bolíbar, I ;
Balanzó, X ;
Verdaguer, A .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :610-616
[7]   Cost analyses of community-acquired pneumonia from the hospital perspective [J].
Bauer, TT ;
Welte, T ;
Ernen, C ;
Schlosser, BM ;
Thate-Waschke, I ;
de Zeeuw, J ;
Schultze-Werninghaus, G .
CHEST, 2005, 128 (04) :2238-2246
[8]   Streptococcus pneumoniae colonisation:: the key to pneumococcal disease [J].
Bogaert, D ;
de Groot, R ;
Hermans, PWM .
LANCET INFECTIOUS DISEASES, 2004, 4 (03) :144-154
[9]   Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness [J].
Brundage, JF .
LANCET INFECTIOUS DISEASES, 2006, 6 (05) :303-312
[10]  
Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P893